BFAR

BFAR is a membrane-associated RING-domain E3 ubiquitin ligase that shapes protein turnover and signaling output in metabolic, immune, and oncogenic contexts by catalyzing substrate-specific ubiquitination (PMID:38294943, PMID:33914044). In hepatocytes, BFAR directly ubiquitylates PNPLA3 and drives its proteasomal/autophagic degradation: it co-immunoprecipitates with PNPLA3, ubiquitylates it in a reconstituted assay with purified proteins, and its loss elevates PNPLA3 protein on hepatic lipid droplets without changing mRNA (PMID:38294943); pharmacologic enhancement of this activity selectively reduces the PNPLA3 I148M variant in a BFAR-dependent manner (PMID:40322074). BFAR diversifies its output through distinct ubiquitin linkages: it adds K63-linked chains to TGFβR1 at Lys268 to activate TGFβ signaling and Th9 cell differentiation (PMID:33914044), whereas it appends K48-linked chains to PRP19 to drive its degradation in gastric cancer, ultimately stabilizing YBX1 and sustaining a neutrophil-driven immunosuppressive microenvironment (PMID:40966304). Beyond direct ubiquitination, BFAR restrains cytokine-induced JAK2 signaling in aged CD8+ T cells by promoting JAK2 deubiquitination, thereby limiting STAT1-dependent tissue-resident memory T cell generation (PMID:39592880), and it physically interacts with the p75 neurotrophin receptor to suppress downstream NFκB and JNK signaling (PMID:22566094). BFAR also promotes gastric cancer proliferation and migration via PI3K/AKT/mTOR signaling and is a direct binding target of bufalin (PMID:37253905).

1. 2012 Medium

   Established the first physical partner and signaling role for BFAR, showing it acts as a cytoplasmic suppressor of receptor-driven stress and survival pathways rather than a passive membrane protein.

   Evidence Membrane yeast two-hybrid screen, reciprocal GST pull-down and co-IP, luciferase reporters for NFκB/JNK, and flow cytometry in PC-12 and HEK293T cells

   PMID:22566094

   Open questions at the time

   • No ubiquitin-ligase activity was demonstrated in this context
   • Mechanism by which BFAR suppresses NFκB/JNK downstream of p75NTR not defined
   • Physiological neuronal relevance not tested in vivo
2. 2021 High

   Defined BFAR as a linkage-specific E3 ligase that activates, rather than degrades, a signaling receptor, resolving how it tunes TGFβ-driven T helper differentiation.

   Evidence BFAR knockout and K268R knock-in mice, ubiquitination assays, Th9 differentiation assays, and in vivo tumor models

   PMID:33914044

   Open questions at the time

   • Structural basis for K268 site selectivity not resolved
   • Whether the same activity operates outside Th9 differentiation untested
3. 2021 Medium

   Identified a nuclear, RNA-associated function for a BFAR isoform, indicating the locus can produce products with roles far from membrane-bound ubiquitination.

   Evidence Co-IP/MS, domain-deletion co-IP, proximity ligation, and fluorescence imaging of EGFP-fusion BFARv3 in cells and oocytes

   PMID:34175335

   Open questions at the time

   • BFARv3 is a mouse-specific isoform with no human ortholog, limiting relevance to canonical human BFAR
   • Functional consequence of NONO/SFPQ binding for RNA metabolism not demonstrated
   • Role in oocytes inferred from expression, not loss-of-function
4. 2023 Medium

   Linked BFAR to a growth-promoting kinase cascade in cancer and identified it as a direct drug target, expanding its role beyond ubiquitination.

   Evidence Human proteome microarray binding screen, molecular docking, proliferation/migration assays, and xenograft model in gastric cancer

   PMID:37253905

   Open questions at the time

   • No ubiquitin-dependent mechanism connecting BFAR to PI3K/AKT/mTOR shown
   • Direct substrate or signaling intermediate not identified
5. 2024 High

   Demonstrated direct, reconstituted E3 ligase activity of BFAR on PNPLA3, establishing it as a bona fide enzyme controlling a lipid-droplet protein in liver.

   Evidence siRNA and overexpression in hepatocytes, reciprocal co-IP, in vitro ubiquitylation with purified recombinant proteins, and Bfar knockout mice with protein/mRNA quantification

   PMID:38294943

   Open questions at the time

   • Ubiquitin chain linkage type on PNPLA3 not specified
   • Balance between proteasomal versus autophagic routing unresolved
6. 2024 High

   Revealed a deubiquitination-promoting activity of BFAR on JAK2, showing it restrains rather than promotes cytokine signaling in aged T cells.

   Evidence Bfar knockout mice, pharmacological inhibitor iBFAR2, JAK2 ubiquitination assays, STAT1 readouts, and CD8+ T cell adoptive transfer tumor models

   PMID:39592880

   Open questions at the time

   • Mechanism by which a RING E3 promotes substrate deubiquitination is not explained
   • Whether BFAR recruits a DUB or directly opposes ubiquitination unknown
7. 2025 Medium

   Confirmed BFAR is pharmacologically tractable for enhancing degradation of the disease-associated PNPLA3 I148M variant.

   Evidence High-content screen of ~820,000 compounds and BFAR-dependent degradation validation in liver-derived cells (NUV-244)

   PMID:40322074

   Open questions at the time

   • Molecular mechanism of compound action on BFAR not resolved
   • In vivo efficacy not established
8. 2025 Medium

   Extended BFAR's K48-ubiquitination activity to PRP19 in gastric cancer and embedded it in a feed-forward immunosuppressive circuit.

   Evidence BFAR knockdown functional studies, K48-linked ubiquitination assays, multiomics, and preclinical gastric cancer models

   PMID:40966304

   Open questions at the time

   • Direct PRP19 ubiquitination by purified BFAR not reconstituted
   • Generality of the NF-κB/S100A8/A9 feed-forward loop across tumor types untested

• How a single RING-domain E3 selects among opposing outcomes — K63 activation, K48 degradation, and promotion of substrate deubiquitination — and what determines its substrate repertoire across tissues remains unresolved.
• No structure of BFAR or its substrate complexes
• Determinants of chain-linkage choice unknown
• No unified model reconciling ligase and deubiquitination-promoting activities